Estudos.

Transcrição

1 Estudos

2 BIOSIL TM Único silício do mundo com tecnologia ch-osa DESCRIÇÃO O BioSil trata-se de ácido ortosilícico ligado a colina através da tecnologia ch-osa (forma de extrusão do líquido ácido, formado pela composição de ácido ortosilício ligado a colina, transformando a solução em um granulado irregular) que garante a integridade da molécula e biodisponibilidade comprovada em aplicações diversas através da forma de beadlets, ideal para manipulação em cápsulas. MECANISMO DE AÇÃO O BioSil acelera a taxa de mineralização óssea e calcificação (prevenindo a osteoporose); estimula a produção de colágeno (melhorando elasticidade da pele e resistência dos fios de cabelo), diminuindo assim a profundidade das linhas de expressão, a fragilidade das unhas, bem como as dores e a rigidez das articulações; reduz a absorção de alumínio no trato digestivo e retarda o seu acúmulo no tecido cerebral, protegendo os neurônios dos danos oxidativos e prevenindo as doenças neurodegenerativas como Alzheimer e Parkinson. INDICAÇÕES Mineralização do tecido ósseo; Melhora da saúde cutânea e capilar; Prevenção contra doenças neurodegenerativas (Alzheimer e Parkinson); DOSE USUAL Recomendação oral de 520mg de BioSil ao dia. SUGESTÕES DE FÓRMULAS BioSil mg Modo de uso: 1 dose ao dia. Indicação: prevenção contra doenças neurodegenerativas. BioSil mg Modo de uso: 1 dose, 3 vezes ao dia, associado ao suplemento abaixo Vitamina K mcg Vitamina D UI Carbonato de cálcio mg Modo de uso: 1 dose, 3 vezes ao dia. Indicação: aumento da densidade mineral óssea. BioSil mg Biotina... 3mg N acetil L cisteína mg Pantotenato de cálcio... 30mg Vitamina B mg Vitamina B mg Cistina... 25mg Goma qsp... 1 dose Modo de uso: 1 dose de cada, 2 vezes ao dia. Indicação: nutricosmético para cabelos e unhas. BioSil mg Oli Ola (Olea europaea - 3% hidroxitirosol) mg Vitamina C mg Shake qsp... 1 dose Modo de uso: dissolver 1 dose em 1 copo com leite ou água, 1 vez ao dia. Indicação: antioxidante, clareador, além de auxiliar a preencher a pele. PRINCIPAIS REFERÊNCIAS LACY F.C.; ARMSTRONG L.L.; GOLDMAN M.P.; LANCE L.L. Drug Information Handbook. American Pharmacists Association. Lexi-Comp. 23ª edição, JURKIĆ, L. M. et al. Biological and therapeutic effects of ortho-silicic acid and some ortho-silicic acid-releasing compounds: New perspectives for therapy. Nutr Metab (Lond). v. 10, n Disponível em:< Acesso em: 16/02/2017, às 14:22.

3 BIOSIL TM ESTUDOS CLÍNICOS Biological and therapeutic effects of ortho-silicic acid and some ortho-silicic acid-releasing compounds: New perspectives for therapy. Silicon (Si) is the most abundant element present in the Earth's crust besides oxygen. However, the exact biological roles of silicon remain unknown. Moreover, the ortho-silicic acid (H4SiO4), as a major form of bioavailable silicon for both humans and animals, has not been given adequate attention so far. Silicon has already been associated with bone mineralization, collagen synthesis, skin, hair and nails health atherosclerosis, Alzheimer disease, immune system enhancement, and with some other disorders or pharmacological effects. Beside the ortho-silicic acid and its stabilized formulations such as choline chloridestabilized ortho-silicic acid and sodium or potassium silicates (e.g. M2SiO3; M= Na,K), the most important sources that release ortho-silicic acid as a bioavailable form of silicon are: colloidal silicic acid (hydrated silica gel), silica gel (amorphous silicon dioxide), and zeolites. Although all these compounds are characterized by substantial water insolubility, they release small, but significant, equilibrium concentration of ortho-silicic acid (H4SiO4) in contact with water and physiological fluids. Even though certain pharmacological effects of these compounds might be attributed to specific structural characteristics that result in profound adsorption and absorption properties, they all exhibit similar pharmacological profiles readily comparable to orthosilicic acid effects. The most unusual ortho-silicic acid-releasing agents are certain types of zeolites, a class of aluminosilicates with well described ion(cation)-exchange properties. Numerous biological activities of some types of zeolites documented so far might probably be attributable to the ortho-silicic acid-releasing property. In this review, we therefore discuss biological and potential therapeutic effects of ortho-silicic acid and ortho-silicic acid -releasing silicon compounds as its major natural sources. Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial. BACKGROUND: Mounting evidence supports a physiological role for silicon (Si) as orthosilicic acid (OSA, Si(OH)4) in bone formation. The effect of oral choline-stabilized orthosilicic acid (ch-osa) on markers of bone turnover and bone mineral density (BMD) was investigated in a double-blind placebo-controlled trial. METHODS: Over 12-months, 136 women out of 184 randomized (T-score spine < -1.5) completed the study and received, daily, 1000 mg Ca and 20 microg cholecalciferol (Vit D3) and three different ch-osa doses (3, 6 and 12 mg Si) or placebo. Bone formation markers in serum and urinary resorption markers were measured at baseline, and after 6 and 12 months. Femoral and lumbar BMD were measured at baseline and after 12 months by DEXA. RESULTS: Overall, there was a trend for ch-osa to confer some additional benefit to Ca and Vit D3 treatment, especially for markers of bone formation, but only the marker for type I collagen formation (PINP) was significant at 12 months for the 6 and 12 mg Si dose (vs. placebo) without a clear dose response effect. A trend for a dose-corresponding increase was observed in the bone resorption marker, collagen type I C-terminal telopeptide (CTX-I). Lumbar spine BMD did not change significantly. Post-hoc subgroup analysis (baseline T-score femur < -1) however was significant for the 6 mg dose at the femoral neck (T-test). There were no ch-osa related adverse events observed and biochemical safety parameters remained within the normal range.conclusion: Combined therapy of ch-osa and Ca/Vit D3 had a potential beneficial effect on bone collagen compared to Ca/Vit D3 alone which suggests that this treatment is of potential use in osteoporosis. NTR Effect of oral intake of choline-stabilized orthosilicic acid on hair tensile strength and morphology in women with fine hair. The appearance of hair plays an important role in people's overall physical appearance and self-perception. Silicon (Si) has been suggested to have a role in the formation of connective tissue and is present at 1-10 ppm in hair. Choline-stabilized orthosilicic acid ("ch-osa") is a bioavailable form of silicon which was found to improve skin microrelief and skin mechanical properties in women with photoaged skin. The effect of ch-osa on hair was investigated in a randomized, double blind, placebo-controlled study. Forty-eight women with fine hair were given 10 mg Si/day in the form of ch-osa beadlets (n = 24) or a placebo (n = 24), orally for 9 months. Hair morphology and tensile properties were evaluated before and after treatment. Urinary silicon concentration increased significantly in the ch-osa supplemented group but not in the placebo group. The elastic gradient decreased in both groups but the change was significantly smaller in the ch-osa group (-4.52%) compared to placebo group (-11.9%). Break load changed significantly in the placebo group (-10.8%) but not in the ch-osa supplemented group (-2.20%). Break stress and elastic modulus decreased in both groups but the change was smaller in the ch-osa group. The cross sectional area increased significantly after 9 months compared to baseline in ch-osa supplemented subjects but not in the placebo group. The change

4 in urinary silicon excretion was significantly correlated with the change in cross sectional area. Oral intake of ch-osa had a positive effect on tensile strength including elasticity and break load and resulted in thicker hair. Effect of oral intake of choline-stabilized orthosilicic acid on skin, nails and hair in women with photodamaged skin. Chronic exposure of the skin to sunlight causes damage to the underlying connective tissue with a loss of elasticity and firmness. Silicon (Si) was suggested to have an important function in the formation and maintenance of connective tissue. Choline-stabilized orthosilicic acid ("ch-osa") is a bioavailable form of silicon which was found to increase the hydroxyproline concentration in the dermis of animals. The effect of ch-osa on skin, nails and hair was investigated in a randomized, double blind, placebo-controlled study. Fifty women with photodamaged facial skin were administered orally during 20 weeks, 10 mg Si/day in the form of ch-osa pellets (n=25) or a placebo (n=25). Noninvasive methods were used to evaluate skin microrelief (forearm), hydration (forearm) and mechanical anisotropy (forehead). Volunteers evaluated on a virtual analog scale (VAS, "none=0, severe=3") brittleness of hair and nails. The serum Si concentration was significantly higher after a 20-week supplementation in subjects with ch-osa compared to the placebo group. Skin roughness parameters increased in the placebo group (Rt:8%; Rm: 11%; Rz: 6%) but decreased in the ch-osa group (Rt: -16%; Rm: -19%; Rz: -8%). The change in roughness from baseline was significantly different between ch-osa and placebo groups for Rt and Rm. The difference in longitudinal and lateral shear propagation time increased after 20 weeks in the placebo group but decreased in the ch-osa group suggesting improvement in isotropy of the skin. VAS scores for nail and hair brittleness were significantly lower after 20 weeks in the ch-osa group compared to baseline scores. Oral intake of ch-osa during the 20 weeks results in a significant positive effect on skin surface and skin mechanical properties, and on brittleness of hair and nails. Partial prevention of long-term femoral bone loss in aged ovariectomized rats supplemented with cholinestabilized orthosilicic acid. Silicon (Si) deficiency in animals results in bone defects. Choline-stabilized orthosilicic acid (ch-osa) was found to have a high bioavailability compared to other Si supplements. The effect of ch-osa supplementation was investigated on bone loss in aged ovariectomized (OVX) rats. Female Wistar rats (n = 58, age 9 months) were randomized in three groups. One group was sham-operated (sham, n = 21), and bilateral OVX was performed in the other two groups. OVX rats were supplemented orally with ch-osa over 30 weeks (OVX1, n = 20; 1 mg Si/kg body weight daily) or used as controls (OVX0, n = 17). The serum Si concentration and the 24-hour urinary Si excretion of supplemented OVX rats was significantly higher compared to sham and OVX controls. Supplementation with ch-osa significantly but partially reversed the decrease in Ca excretion, which was observed after OVX. The increase in bone turnover in OVX rats tended to be reduced by ch-osa supplementation. ch- OSA supplementation increased significantly the femoral bone mineral content (BMC) in the distal region and total femoral BMC in OVX rats, whereas lumbar BMC was marginally increased. Femoral BMD was significantly increased at two sites in the distal region in OVX rats supplemented with ch-osa compared to OVX controls. Total lumbar bone mineral density was marginally increased by ch-osa supplementation. In conclusion, ch-osa supplementation partially prevents femoral bone loss in the aged OVX rat model. Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old. There are inconsistent findings on the effects of vitamin K on bone mineral density (BMD) and undercarboxylated osteocalcin (UcOC). The present intervention study evaluated the effect in subjects over 60-yr-old. The vitamin K group (vitamin K vitamin D calcium supplement; 15 mg of vitamin K2 [menatetrenone] three times daily, 400 IU of vitamin D once a day, and 315 mg of calcium twice daily) and the control group (vitamin D calcium supplement) were randomly assigned. During the six months of treatment, seventy eight women participated (38 in the vitamin K group and 40 in the control group) and 45 women completed the study. The baseline characteristics of study participants did not differ between the vitamin K and the control groups. In a per protocol analysis after 6 months, L3 bone mineral density has increased statistically significantly in the vitamin K group compared to the control group (0.01 ± 0.03 g/cm(2) vs ± 0.04 g/cm(2), P = 0.049). UcOC concentration was also significantly decreased in the vitamin K group (-1.6 ± 1.6 ng/dl vs -0.4 ± 1.1 ng/dl, P = 0.008). In conclusion, addition of vitamin K to vitamin D and calcium supplements in the postmenopausal Korean women increase the L3 BMD and reduce the UcOC concentration.

5 REFERÊNCIAS JURKIĆ, L. M. et al. Biological and therapeutic effects of ortho-silicic acid and some ortho-silicic acid-releasing compounds: New perspectives for therapy. Nutr Metab (Lond). v. 10, n Disponível em:< Acesso em: 16/02/2017, às 14:22. SPECTOR, T. D. et al. Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial. BMC Musculoskelet Disord. v. 9, n Disponível em:< Acesso em: 16/02/2017, às 15:03. WICKETT, R. R. et al. Effect of oral intake of choline-stabilized orthosilicic acid on hair tensile strength and morphology in women with fine hair. Arch Dermatol Res. v. 299, n. 10, p Disponível em:< Acesso em: 16/02/2017, às 15:06. BAREL, A. et al. Effect of oral intake of choline-stabilized orthosilicic acid on skin, nails and hair in women with photodamaged skin. Arch Dermatol Res. v. 297, n. 4, p Disponível em:< Acesso em: 16/02/2017, às 15:10. CALOMME, M. et al. Partial prevention of long-term femoral bone loss in aged ovariectomized rats supplemented with choline-stabilized orthosilicic acid. Calcif Tissue Int. v. 78, n. 4, p Disponível em:< Acesso em: 16/02/2017, às 15:16. JE, S.H. et al. Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old. J Korean Med Sci. v. 26, n. 8, p Disponível em:< Acesso em: 10/07/2017, às 13:26.